Comparing the Levels of Harmful Compounds in Smokers That Either Continue To Smoke, Quit Or Switch To THS2.2 Menthol*

Presented by: Yin Boll


Philip Morris Products S.A., Neuchâtel, Switzerland (part of Philip Morris International group of companies), 2Daytona Beach, Florida, United States, 3Dallas, Texas, United States.

The study was conducted in the US in 2013/14 according to ICH GCP, approved by an IRB and registered on ClinicalTrials.gov (NCT01989156).

F. Lüdicke

Presented by: Yin Boll

SUBJECTIVE EFFECTS

Achieved an equally efficient suppression of urge to smoke compared to smoking-related disease. However, THS2.2 showed less satisfaction for THS2.2 compared to cigarette (CC). However, THS2.2 achieved an equally efficient suppression of urge to smoke compared to CC over the entire exposure period. THS2.2 was well tolerated.

CONCLUSIONS

- Switching from CC to THS2.2 is associated with substantial reductions in exposure to selected harmful and potentially harmful constituents (except 5-DMBA, which showed similar levels for THS2.2, CC and SA groups indicating that it is not a sensitive marker to discriminate between smoking and SA; data not shown) sustained throughout the 3-month exposure period. The kinetics and the magnitude of the decrease of the BoExp levels in THS2.2 were close to those observed in SA.
- The interpretation of the preserved SA effect is limited as only 9 subjects were included in THS2.2. No SAE was reported after randomization.
- Similar exposure to nicotine between the THS2.2 and CC, comparable reduction in NNK air道 in 23 subjects (59.0%) in SA were reported with decreased hemoglobin and increased lymphocyte count as related to THS2.2. No SAE was reported after randomization.
- Following randomization, 114 AEs in 52 subjects (65.0%) in THS2.2, 32 AEs in 23 subjects (59.0%) in SA were reported with decreased hemoglobin and increased lymphocyte count as related to THS2.2. No SAE was reported after randomization.
- The biomarker S-DMBA was also measured; however this biomarker indicated that it is not sensitive enough to discriminate between the different groups; Data not shown.

Clinical risk measurements were selected based on:

1. Their association with smoking-related disease
2. Those showing a relationship between the number of cigarettes smoked and their levels
3. Those that show reversibility upon smoking cessation

SAFETY

Prior to randomisation, 84 adverse events (AEs) were observed in 62 (37.6%) of 165 subjects enrolled. One subject reported 2 serious adverse events (SAE) (cancer and diabetic ketoacidosis) and was not randomized. Following randomization, 114 AEs in 52 subjects (65.0%) in THS2.2, 32 AEs in 23 subjects (59.0%) in CC and 49 AEs in 23 subjects (59.0%) in SA were reported with decreased hemoglobin and increased lymphocyte count as most frequently reported AEs. Seven mild AEs in THS2.2 were reported as related to smoking abstinence. No SAE was reported after randomization.

SPECIAL INTERESTS

Subjective effects of smoking were assessed by means of the brief version of the Nicotine Dependence With Health Symptoms, and the modified Cigarette Evaluation Questionnaire. Product evaluation at Day 90 showed slightly less satisfaction for THS2.2 compared to cigarette (CC). However, THS2.2 achieved an equally efficient suppression of urge to smoke compared to CC over the entire exposure period. THS2.2 was well tolerated.

High density lipoprotein-cholesterol, total white blood cell count, forced expiratory volume in 1 second, soluble intercellular molecule adhesion-1, 8-epi-prostaglandin F2α, and 11-dehydro-thromboxane B2 were measured as clinical risk endpoints (CREs). Due to the study design, targeting to the assessment of BoExp limited sample size, adherence to the allocated regimen, the variability of the CRE results did not allow a conclusive interpretation of the results although most CREs started to show favorable changes shifting in the direction of SA.

At Day 90, 75% of 165 subjects enrolled. One subject reported 2 serious adverse events (SAE) (cancer and diabetic ketoacidosis) and was not randomized. Following randomization, 114 AEs in 52 subjects (65.0%) in THS2.2, 32 AEs in 23 subjects (59.0%) in CC and 49 AEs in 23 subjects (59.0%) in SA were reported with decreased hemoglobin and increased lymphocyte count as most frequently reported AEs. Seven mild AEs in THS2.2 were reported as related to smoking abstinence. No SAE was reported after randomization.

The biomarker S-DMBA was also measured; however this biomarker indicated that it is not sensitive enough to discriminate between the different groups; Data not shown.

The study was conducted in the US in 2013/14 according to ICH GCP, approved by an IRB and registered on ClinicalTrials.gov (NCT01989156).

*For more detailed information please refer to original poster * Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in the U.S.: A comparison with continued cigarette use or smoking abstinence.